Tag: Alzheimer's disease

Longer Life Exposure to Oestrogen Linked to Better Cerebrovascular Health

Photo by Ravi Patel on Unsplash

Women who had a longer reproductive period and had used or are using hormone replacement therapy showed fewer signs of damage to the small blood vessels in the brain later in life. This is shown by a study led by Karolinska Institute’s researchers, published in the journal Neurology.

In this new study, the researchers examined 352 women from Gothenburg. All were aged 70 with no signs of impaired cognitive functioning. The participants’ brains were scanned using magnetic resonance imaging (MRI) at the age of 70 and again five years later.

The researchers also had data on the age at first menstruation and the onset of the menopause, as well as previous use of the contraceptive pill and hormone replacement therapy during the menopause. This was compared with, amongst other things, signs of small-vessel disease – that is, damage to the brain’s tiniest blood vessels – the microstructure of the white matter, and the thickness of the cerebral cortex in areas vulnerable to Alzheimer’s disease.

A longer reproductive period – that is, the time between the first menstruation and the menopause – was associated with lower small-vessel disease burden in the brain. The use of hormone replacement therapy during the menopause was also associated with less small-vessel disease and a more favourable microstructure in the brain’s white matter. Women who had used both the contraceptive pill during their reproductive years and hormone replacement therapy during the menopause showed the most favourable profile for their vascular brain health.

May have cumulative effects

The researchers behind the study note that women not only are more likely than men to develop Alzheimer’s disease, a difference that may be partly related to oestrogen fluctuations across the lifespan. The new findings suggest that these hormonal exposures may also influence the health of the brain’s blood vessels.

”Our results suggest that hormonal exposure across different periods of a woman’s life may have cumulative effects also on the cerebrovascular health in later life. The findings suggest that the brain’s blood vessels may play an important role in the link between oestrogen and brain ageing,” says Anna Marseglia, assistant professor at the Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, and senior author of the study.

One limitation of the study is that data on hormone use were self-reported, and there was a lack of detailed information on, for example, when treatment began, the dose and the type of treatment.

”Furthermore, the study is an observational study, and we cannot therefore determine cause and effect. The results cannot therefore be used as a basis for recommending hormone therapy for preventive purposes”, says first author Giulia Lorenzon, researcher at Yale University and former postdoctoral researcher at the Department of Neurobiology, Care Sciences and Society, Karolinska Institutet.

Source: Karolinska Institutet

Figuring out How the BCG Vaccine Reduces Dementia Risk

Photo by Raghavendra V Konkathi on Unsplash

Bacillus Calmette-Guerin (BCG), a vaccine widely used to prevent tuberculosis and treat bladder cancer may also have properties that reduce the risk for dementia, according to new findings in a study of mice. BCG is a live, weakened vaccine made from an altered strain of the bacterium Mycobacterium bovis. The findings from this study, which was led by a team of Johns Hopkins Medicine researchers and funded by the National Institutes of Health, published today in Science Advances. 

The researchers found that mice genetically engineered to have biological symptoms of dementia and that received the BCG vaccine were less likely to show hallmark signs of the disease, such as neurofibrillary (tau) tangles in the brain, sustained immune cell activation and memory loss compared to mice that received no vaccine. 

“We’re hard at work trying to understand the detailed mechanism for how it works, but this research points to early clues that aspects of trained immunity are likely driving this response,” says William Bishai, MD, PhD, co-director of the Johns Hopkins Center for Tuberculosis Research. 

Bishai explains that trained immunity refers to the ability of mammals’ innate immune system cells to take on an expanded role. Following an initial stimulus, innate immune cells, often monocytes and macrophages, learn how to identify and respond to future threats that are different from the first. (Typically, other immune system cells, like T cells, take on this type of adaptive and learned response.)

In this case, Bishai believes that myeloid cells – innate immune cells – in the central nervous system and brain are using information from BCG to recognise and help the body respond to the formation of plaques and tangles characteristic of Alzheimer’s disease and related dementias. 

For this new study, Bishai and the researchers created a controlled experiment with mice with symptoms of dementia, specifically marked by tau pathology or a clumping of tau proteins in the brain representing late stages of the disease. 

They divided mice into those that received the BCG vaccine and those that received a saline injection. An additional comparison group included age-matched mice that did not have dementia and that also received the saline injection.Mice in the BCG treatment group received the vaccine at 3 months of age. Multiple assessments, based on brain imaging, memory recall (through an object recognition test) and indicators of disease, including neuroinflammation and the expression of genes linked to Alzheimer’s disease, were conducted eight to nine months later. 

The researchers found that mice who received BCG were about five times more likely to have signs of reduced tau deposits in their brain. They were also four times less likely to have markers of sustained inflammation – signalling that their immune cells had already likely responded to tau by clearing out some of the tangles and had created a stable or protective immune response. 

Untreated mice also showed activation of 716 genes connected to Alzheimer’s disease, cell death and neuroinflammation, and BCG normalised all but nine of these. Compared to untreated mice, the mice who received BCG were less likely to have signs of brain atrophy and also more likely to live longer and perform better on tasks related to remembering and identifying objects. 

BCG seems to be reducing the degree of hyperinflammation in the brain – which is a good thing – and it may be doing it through a trained immune cell mechanism,” says Bishai. “There are a number of other characteristics of trained immunity that we are studying in the lab now.” 

This research, Bishai says, is believed to be the first to study BCG and dementia in mouse models with tau pathology (specifically showing how immune cells may play a role in clearing neurofibrillary tangles). Others have found similar findings with BCG and improved cognition in amyloid mouse models – which represent earlier stages of the disease marked by plaque formation. 

These findings also follow observational studies in humans – those not designed to show cause and effect – that have linked off-target effects of vaccines to a reduced incidence of dementia. 

Several previous studies, which are cited in the paper, have found that BCG used as an immunotherapy for non-muscle invasive bladder cancer was linked to a 12% to 78% reduced risk of dementia throughout a three- to 15-year period. The shingles vaccine has also been linked to a 20% reduced incidence of dementia.

Source: Johns Hopkins Medicine

Alzheimer’s Treatment Trial Times Halved with New Approach

Photo by Kampus Production

A first-of-its-kind clinical trial has launched in the UK, which could cut years from the search for treatments that work for people with Alzheimer’s disease.

The national trial is called AD-SMART (Alzheimer’s disease Systematic Multi-arm Adaptive Randomised Trial). It is led by the UK Dementia Research Institute (UK DRI) and Alzheimer’s Research UK (ARUK), in partnership with the National Institute for Health and Care Research, the Medical Research Council (MRC) and Health Data Research UK, with ongoing UK government funding.

It will test multiple drugs simultaneously, starting with two repurposed medicines already used to treat type 2 diabetes and attention deficit hyperactivity disorder. Groups of participants will each begin treatment with a different drug. The study will examine whether these medicines can lessen symptoms such as memory and thinking problems, and help people maintain their quality of life as the disease progresses. Testing drugs that are already approved to treat other conditions and known to be safe means that, if successful, treatments can reach people living with Alzheimer’s much faster than a medicine developed from scratch. As well as repurposed drugs, the trial is designed to test new potential treatments coming through the research pipeline.

Heather Ransome, 67, from the Isle of Wight, was diagnosed with Alzheimer’s in 2024. She said: “Before my diagnosis, my partner and I were going on lots of cruises and coach holidays, enjoying retirement together. We still enjoy life, but I’m worried about my condition getting worse. I’m not the sort of person who gets upset, but being told you have Alzheimer’s is quite upsetting. There weren’t many treatment options available, and the one drug I was offered has been around for many years. Getting involved with AD-SMART has given me some hope for the future. It’s not too taxing, just some extra tablets to take every day. I don’t know whether I’m being given the active treatment, but if it helps me, or helps others in future, that feels positive. I would encourage anyone who thinks they might be eligible to sign up and speak to the team.”

The Prime Minister Andy Burnham said: “I know how it feels to lose a loved one to dementia and have seen first-hand the devastating impact this illness has on families. That’s why I’m proud to see this trial being launched in the UK, so that cutting edge treatments can reach patients here as soon as possible. I have made dementia research a national priority. I want Britain to be the leading nation, making the breakthroughs that change people’s lives.”

AD-SMART is a multi-arm, multi-stage platform trial. Several drugs are tested at the same time, and the results compared with one group of participants taking a dummy drug (placebo). This means more people receive an active treatment than would in a traditional trial. Results are checked at regular stages throughout the trial and any drug that isn’t showing benefit can be dropped quickly, with new drugs added in its place. Overall, this means fewer participants end up receiving ineffective drugs. Testing several drugs against one shared placebo group means that compared with a traditional trial, the time to evaluate treatments can be more than halved, which also reduces costs.

The trial is being delivered by a team at Imperial College London, the UCL Innovative Clinical Trials Unit and the MRC Centre of Research Excellence in Clinical Trial Innovation (UCL), the University of Oxford, and Dementias Platform UK. Leading Alzheimer’s experts from across the UK will be providing support.

Chief Investigator, Dr Paresh Malhotra, Group Leader at the UK Dementia Research Institute (UK DRI) Centre for Care Research and Technology at Imperial College London, said: “For too long, Alzheimer’s research has moved at the pace of one drug, one trial, one answer, sometimes taking a decade or more before we know if we’ve found something that works. We are applying advances from cancer and other conditions to accelerate testing of treatments for people with Alzheimer’s disease. The way AD-SMART is set up means we’re testing several treatments at the same time, and those that don’t show promise can be quickly stopped. Then we can start testing something else. That’s the best way to get effective treatments to patients as quickly as we can.”

The first trial participants have been recruited at Cambridgeshire and Peterborough NHS Foundation Trust and Surrey and Borders Partnership NHS Foundation Trust. Sites based at Imperial College Healthcare NHS Trust, Edinburgh and Southampton are also now open. Up to 20 NHS sites are expected to open across the UK over the next 12 to 18 months and more than 30 are planned overall. Researchers aim to recruit 1,200 participants across the UK to test these first two drugs. They expect to finish evaluating the first drugs in 2030, in around four years’ time. During this initial four-year period, the team expect additional drugs to be added into the trial for testing.

AD-SMART is the first trial of this kind for people living with Alzheimer’s, but the model has already proven itself in the UK. MND-SMART, a similar platform trial for motor neuron disease, also led by the UK DRI, concluded that its first drugs tested were ineffective in just over three years. This process would normally take at least eight years. The trial has now moved on to testing other promising drugs.

MRC Executive Chair Dr Patrick Chinnery said: “Innovative clinical trials like AD-SMART are crucial to accelerating progress in health research, generating robust evidence at pace and supporting faster translation of research into patient benefit. This is particularly important in dementia and Alzheimer’s disease research, where there is an urgent clinical need for new therapeutic options. This UK DRI-led trial draws on expertise across the MRC’s institutes, the MRC Centre of Research Excellence in Clinical Trial Innovation, and the Dementia Trials Accelerator, which speeds up recruitment into clinical trials, to evaluate promising interventions more rapidly, and hopefully bring new treatment options to the people who need them.”

Science Minister, Chris McDonald MP said: “Dementia has a devastating impact on millions of people, both for those living with the illness and for their friends and families. There is still so much we need to learn about how this disease works so we can then find the best ways to treat it, but this programme can help us bridge the gap. AD-SMART will help to uncover potential new treatments faster by exploring how existing drugs might be used to treat dementia, giving hope that we might be able to find ways to improve patients’ quality of life in the future.”

Source: UK Research and Innovation

Diabetes Masks Alzheimer’s Biological Changes in the Brain

Neurons in the brain of an Alzheimer’s patient, with plaques caused by tau proteins. Credit: NIH

Research led by King’s College London suggests diabetes may mask biological changes linked to Alzheimer’s disease, raising the possibility that the underlying biology of Alzheimer’s differs between people with and without diabetes.

Diabetes is a major risk factor for Alzheimer’s disease, and the two conditions share several biological processes, including mitochondrial dysfunction, inflammation, oxidative stress and impaired insulin signalling. This suggests that diabetes may contribute to the progression of changes in the brain associated with Alzheimer’s disease.

The paper, published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, examined mitochondrial DNA copy number (mtDNA-CN) in post-mortem samples from three regions of the human brain: the hippocampus, amygdala and cerebellum.

The team found that Alzheimer’s disease and diabetes were associated with opposing changes in mitochondrial DNA. Alzheimer’s was associated with lower mtDNA-CN, while diabetes was associated with higher levels across all three brain regions.

When people with diabetes were removed from the analysis, mtDNA-CN was 19 to 30 per cent lower in people with Alzheimer’s compared with cognitive controls. In contrast, among people with Alzheimer’s, those with diabetes had significantly higher mtDNA-CN than those without diabetes. Levels were 41 per cent higher in the hippocampus, 52 per cent higher in the amygdala and 64 per cent higher in the cerebellum. Surprisingly, all diabetes cases, including those with and without dementia, had higher mtDNA in these three regions than non-diabetic controls.

These opposing effects suggest that including people with diabetes in Alzheimer’s studies could reduce or mask differences associated with Alzheimer’s itself.

The findings suggest that diabetes may change the way Alzheimer’s disease is associated with mitochondrial changes, rather than simply being a background health condition. This could mean that the relationship between Alzheimer’s and mitochondrial DNA may be different in people with diabetes compared with those without diabetes.

“The key finding of our study in relation to Alzheimer’s disease is that grouping both diabetic and non-diabetic data for mtDNA-CN together can result in loss of real changes which may be important in disease mechanisms. Our research supports the growing view that Alzheimer’s disease can affect people in different ways at a biological level, and that conditions such as diabetes may contribute to these differences.”

Senior author Dr Afshan Malik

“We were surprised to find that mtDNA-CN was higher in the brains of people with diabetes. We don’t yet know whether this represents a response to cellular stress, a compensatory mechanism, or something else and what this means for the brain function. Our next step is to use multi-omics approaches to understand the biological consequences of this change and how it may affect brain function.”

First author Dr Aakruti Kaikini

The study provides a possible explanation for why previous studies of mitochondrial dysfunction in Alzheimer’s disease have produced conflicting results, potentially making it more difficult to diagnose patients.

In the future the researchers hope the results could be important for developing better ways to identify and understand Alzheimer’s disease, tailoring treatments to individual patients and designing future dementia clinical trials.

Source: King’s College London

Neurosurgery Samples Reveal New Drug Target for Alzheimer’s Disease

Promising anti-inflammatory drug target can block receptors in the brain and potentially dampen down pathways to major brain conditions

Photo by Natanael Melchor on Unsplash

Inflammatory conditions in the brain, including traumatic brain injury and degenerative diseases like Alzheimer’s could be targeted with an existing drug thanks to new research that shows it can work in brain cells.

In a study published in Brain, a team led by Professor Nicholas Barnes at the University of Birmingham has identified a critical receptor that when blocked inhibits neuroinflammation. This first-of-its-kind work with human brain tissue demonstrates how interrupting this pathway could open the door to treating a wide spectrum of chronic neurological conditions. These include not only traumatic brain injury (TBI), but also neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease, and even psychiatric disorders such as depression and psychosis, these latter conditions are increasingly understood to have a neuroinflammatory component.

Using live cultures of human brain cells and slices of brain tissue obtained during neurosurgery, the researchers investigated the role of a receptor known as the P2X7 receptor, which is responsible for triggering inflammatory signalling.

This exciting discovery marks a major step toward repurposing existing therapeutics to combat neuroinflammation at its source. The identification of this receptor could have far-reaching implications for some of the most debilitating and widespread brain disorders

Professor Nicholas Barnes, Professor of Neuropharmacology

Their findings reveal that these P2X7 receptors drive the release of key proteins called cytokines involved in controlling inflammation. By blocking this receptor with a specific antagonist, the team was able to significantly reduce the inflammatory response in human brain tissue.

Professor Nicholas Barnes from the College of Medicine and Health at the University of Birmingham and corresponding author of the paper said: “This exciting discovery marks a major step toward repurposing existing therapeutics to combat neuroinflammation at its source. The identification of this receptor could have far-reaching implications for some of the most debilitating and widespread brain disorders such as Alzheimer’s Disease, Parkinson’s and Multiple Sclerosis, or inflammation-linked psychiatric conditions like schizophrenia and depression”.

Brain’s resident immune sentinels

In order to study how brain cells respond to and manage inflammation, the team developed a way of turning a type of white blood cell into microglia, replicating a normal cellular transformation that has recently been identified to occur in the brain as a natural part of human ageing. These microglia are the central coordinators of the immune system in the brain.

Using readily accessible human peripheral monocytes taken from blood samples, the researchers converted them into microglia-like cells that were used to see how microglia are likely to respond to the inflammation signals. Using the P2X7 receptor antagonist, the team were then able to interrupt the triggers that these microglia give off as they are damaged and die.

Professor Barnes said: “Studying human microglia has long been a major challenge: once removed from their native brain environment, they rapidly lose their defining characteristics, likely due to the absence of critical regulatory signals. Our approach involved the use of monocyte-derived microglia which provide a powerful, scalable, and virtually unlimited platform for studying human microglial biology with unprecedented precision.

“Having identified the response in the human monocyte-derived microglia, this provided the impetus to translate these findings with human brain obtained following neurosurgical procedures. This successful translation means the next stage for this research is the development of clinical trials in patients with neurodegenerative conditions and patients with TBI where there are no effective pharmacological treatments to reduce the neuroinflammation and arising damage.”

Source: University of Birmingham

Study Links Deep-sleep Loss to Alzheimer’s-related Protein Buildup

As tau builds up in the brain, non-REM brain waves necessary for memory formation become erratic.

Photo by SHVETS production

As we age, our episodic memory gets weaker. Sensory details of life’s moments – such as where we parked our car in a busy parking lot – become harder to recall, though scientists don’t yet know why. This is true for almost all of us, but for some people, including those who are developing Alzheimer’s disease, the scale of memory loss can be devastating.

New research by UC Berkeley neuroscientist Omer Sharon and colleagues, directed by former Berkeley sleep researcher Matthew Walker, may help explain why. The researchers identified a link between changes in brain wave patterns during non-REM sleep, poorer episodic memory formation and buildup of the protein tau, a known marker for development of Alzheimer’s disease, in the brain’s frontal cortex.

“This is the first time we’ve shown this relationship between tau and how it messes with memory consolidation by attenuating traveling slow waves that originate in the frontal cortex,” said Sharon, a postdoctoral researcher at UC Berkeley’s Center for Human Sleep Science. The findings were published in the journal Nature Neuroscience on Sept 11.

Many of us are familiar with the rapid eye movement phases of sleep, when slumbering people’s eyes flicker back and forth under their lids and most dreaming occurs. But non-REM sleep – a deeper form of sleep with little, if any, dreaming – is crucial for brain health. 

During non-REM sleep, neurons shut down in slow, synchronised waves that move across the brain, beginning in the frontal cortex. 

This coordinated shutdown has been observed only during deep sleep, and may be one reason why we sleep.

Omer Sharon, UC Berkeley Postdoctoral Researcher

“Each slow wave reflects an enormous population of neurons switching off and back on together,” Sharon said. “Our study shows that for memory, it’s critical that these events cascade in sequence across large parts of the brain. This coordinated shutdown has been observed only during deep sleep, and may be one reason why we sleep.”

As we age, tau proteins build up in many people’s brains. For them, these waves become irregular and less synchronised and travel shorter distances. This slow-wave breakdown is in turn linked to dwindling memory consolidation, cognitive decline and the development of Alzheimer’s disease. 

To study this correlation, the researchers used electroencephalograms (EEGs) to measure brain waves during sleep. They compared results from cognitively healthy participants in their early 20s to those from their mid-60s to mid-70s. In the younger adults, clusters of slow brain waves traveled roughly the length of a handspan across the scalp during non-REM sleep. In the older adults, the waves traveled shorter distances and were more solitary. 

Using positron emission tomography (PET) scans conducted with Dr. William Jagust, a professor emeritus in public health and neuroscience at Berkeley, the researchers traced  radioactive markers injected into the bloodstream to measure brain function. The scans confirmed that the buildup of tau in the frontal cortex of older participants correlated with those long wave breakdowns. 

Three columns of three images each that are PET scans of brains. Each column contains
In healthy older study participants, PET scans revealed the protein tau building up over time in their frontal cortices. This buildup correlates with shortened, isolated slow brain waves during sleep and with memory loss.Courtesy of Omer Sharon/UC Berkeley Department of Psychology

This interference with slow brain waves shows up even before patients develop Alzheimer’s disease. “These people did not have Alzheimer’s,” Sharon said. “They had tau in their brains, but with subclinical impacts. Their memory decline was within the normal range for their age.” Indeed, Alzheimer’s symptoms appear along a spectrum at first, Sharon said, with the amount of tau in a person’s brain correlating to cognitive performance.

The researchers also measured corresponding changes in memory consolidation by giving participants word associations at night, then testing how well they remembered them the next day. People with more solitary, shorter-reaching slow waves – what the researchers called “lonely waves” – remembered less material.

After several years, a subset of participants was retested. Those whose frontal tau had increased over the years had worsened slow-wave coordination and lessened overnight memory retention. While this does not prove that frontal cortex tau buildup causes memory loss, it indicates that there is a connection between the protein and episodic memory loss that is related in some way to brain wave changes. 

PET scans are expensive and require specialised equipment, making them hard to arrange, so the researchers worked with neurologist Yo-El Ju at Washington University in St. Louis to measure tau levels in the spinal fluid of a different group of elderly people. Although this test didn’t reveal tau buildup specifically in the frontal cortex, a similar pattern emerged: The spinal fluid from participants whose brains had more solitary slow waves during sleep contained higher ratios of tau to another Alzheimer’s disease linked protein, amyloid.

Sharon found it convincing to see these different methods arrive at converging results. “It’s collected in a totally different place and in a different cohort, so I think that adds to the strength of the evidence,” he said.

Altogether, the multiple measures led the researchers to connect tau buildup, a known form of Alzheimer’s pathology, with a specific kind of brain function. “This longitudinal correlation suggests that Alzheimer’s disease pathology is associated with a disruption of this main sleep feature,” Sharon said. 

And though it remains unclear to researchers why memory loss is correlated with aging, the findings suggest that the connection is more complex than previously thought. “It’s not just about age,” Sharon said. “It’s how much pathology you have in frontal areas where global waves originate.” It’s also about sleep quality – a hard-to-define concept for which slow waves seem to be proxies. 

“We can see tau and lonely waves rising together over time,” Sharon said. “What we cannot yet say is which leads – and that question will shape how we design interventions.” 

Source: University of California Berkeley

Human-safe Drug Repairs DNA in a Mouse Model of Alzheimer’s

Source: Pixabay CC0

A drug, that has previously been shown to be safe and tolerated by humans, reduces multiple disease-linked features of Alzheimer’s in a mouse model of the disease.

Neuroscientists from King’s College London have developed an approach that targets a key protein to tackle several features of Alzheimer’s disease in one go. They found that KCL-286, a drug that has previously passed Phase 1 safety trials originally developed for spinal cord injury, was able to lessen many disease-linked features of Alzheimer’s. 

“KCL-286 is a first-in-class, orally bioavailable small molecule that has already successfully cleared Phase 1 human safety and tolerability trials. This will dramatically cut down the traditional multi-year timeline required for new drug development,” commented Professor Jonathan Corcoran, Professor of Neuroscience at the Institute of Psychiatry, Psychology & Neuroscience at King’s College London. 

The causes of Alzheimer’s disease are highly complex. It is classically characterised by toxic build-up of proteins called amyloid-beta and tau, ultimately resulting in neuron death. While amyloid-beta and tau have been the main targets for drug development, approved drugs targeting amyloid-beta alone have limited but measurable clinical success.

Other features of the disease, such as DNA strand breaks and inflammation, have only recently been investigated as potential disease-modifying targets. DNA damage and inflammation occur in the earliest stages of the disease, suggesting they may be important targets for treatment. The new drug was found to repair DNA breaks and reduce inflammation in a mouse model of Alzheimer’s disease, providing a broader therapeutic strategy than approaches focused on individual disease hallmarks such as amyloid and tau.

“Our findings demonstrate that KCL-286 not only targets DNA damage but also reduces inflammation, two processes that occur very early in Alzheimer’s disease progression. This highlights its potential as a disease-modifying therapy rather than simply addressing symptoms,” said Dr Maria Goncalves, who project managed the drug development. 

The drug used in the new study, KCL-286, activates a specific protein in the retinoic acid pathway, a series of chemical reactions in the body used to process vitamin A. Previous studies have linked the deficits in this molecular pathway to amyloid-beta deposits forming in rat brains, similar to those seen in Alzheimer’s disease.

KCL-286 has previously been shown to help repair DNA double-strand breaks in neuropathic pain, leading researchers to hypothesise that it might be a suitable candidate for targeting the same type of DNA damage in Alzheimer’s disease.

DNA double-strand breaks are like a rope snapping completely in two, rather than just fraying at the edges. We found that KCL-286 promotes repair of these breaks, allowing us to target a key feature of Alzheimer’s disease.

Professor Jonathan Corcoran, Professor of Neuroscience at the Institute of Psychiatry, Psychology & Neuroscience at King’s College London.

Shared molecular pathways between spinal acute spinal cord injury and Alzheimer’s disease, established by the same team at King’s, hinted that KCL-286, may lessen some markers of Alzheimer’s in neurons.

Natasha Hill, one of the first authors on the paper, said: “To develop an effective treatment for Alzheimer’s disease, we need to tackle multiple aspects of the disease. KCL-286 was able to target multiple disease-relevant cellular pathways, some of which are initiated very early in the disease course.”

Source: King’s College London

Before the Memory Fades: Scientists Discover a Potential Early Warning Sign of Alzheimer’s

New research suggests Alzheimer’s disease may affect the brain’s ability to adapt before memory problems become obvious, offering clues for earlier interventions.

Created with Gencraft. CC4.0

When most people think about Alzheimer’s disease, memory loss is usually the first thing that comes to mind. Forgetting a loved one’s name, missing appointments or repeatedly misplacing everyday items are often considered early warning signs.

But what if the disease begins affecting the brain long before memory problems become noticeable? New research from scientists at Texas A&M Health suggests that another change in brain function may appear even earlier: difficulty adapting when circumstances change.

In a recent study, researchers found that animal models with Alzheimer’s-related brain changes developed problems with cognitive flexibility months before they showed signs of memory impairment. Cognitive flexibility refers to the brain’s ability to adjust behavior, learn new rules and adapt when situations change.

“We found that this function was impaired before we could detect deficits in spatial memory,” said neuroscientist Jun Wang, PhD, professor in the Texas A&M University Naresh K. Vashisht College of Medicine at Texas A&M Health.

The findings suggest memory loss is not always the earliest sign of Alzheimer’s disease. Instead, they suggest that by the time memory problems become noticeable, disease-related brain changes may already be underway. Paying attention to earlier changes in executive function may provide additional clues about the earliest stages of the disease.

Testing the brain’s ability to adapt

To investigate these early changes, researchers used a widely studied animal model of Alzheimer’s disease known as 5xFAD. These models develop amyloid-beta plaques, one of the key features found in the brain of humans with Alzheimer’s disease.

The research team focused on measuring cognitive flexibility through a method called reversal learning. In this type of test, animal models first learn that a particular action leads to a reward. Once that association is established, researchers change the rules and reward a different action instead.

Healthy animal models quickly adjusted and learned the new rule. 5xFAD models struggled to adapt, continuing to follow the original rule even after it no longer led to a reward. What made the finding particularly significant was that although they struggled to adapt to change, the animal models still performed normally on tests of spatial memory, which is the ability to remember where things are and helps us navigate our surroundings.

A hyperactive brain circuit

 The researchers then discovered abnormally high activity in the medial prefrontal cortex, the region involved in decision-making, behavioral flexibility and goal-directed actions. This hyperactivity extended through a network connecting the prefrontal cortex and the striatum, two brain regions that work together to help people adjust their behaviour when circumstances change.

The team also found reduced activity in a specialised group of brain cells called cholinergic interneurons. These cells play an important role in learning and behavioral adaptation, and their decreased activity closely matched the cognitive flexibility deficits observed in the animal models.

Together, the findings suggest that Alzheimer’s disease may affect neural circuits involved in executive function and adaptability before causing noticeable memory problems.

Breaking a harmful cycle

Scientists have known that amyloid-beta production increases when neurons are highly active. At the same time, amyloid-beta can make neurons even more excitable. This creates a potentially harmful cycle in which increased brain activity promotes amyloid accumulation, which then drives even more activity.

Wang describes this cycle as a “chicken-and-egg” problem. To test whether breaking this cycle could help, the researchers used a targeted approach to quiet the overactive brain pathway. The method worked like a temporary “dimmer switch,” allowing the team to reduce the activity of selected brain cells in the front part of the brain that send signals to the striatum, a region involved in flexible behaviour.

The intervention improved cognitive flexibility, restored more normal patterns of brain activity and reduced amyloid-beta accumulation. The benefits persisted after treatment ended, suggesting lasting changes within the affected neural circuits.

Implications for Alzheimer’s research

Although the study was conducted in animal models and further research is needed to determine whether the same pattern occurs in humans, the findings point to a promising new direction for Alzheimer’s research and potential future treatments.

Rather than focusing exclusively on memory loss, scientists may need to pay closer attention to early changes in cognitive flexibility and executive function that may provide clues that Alzheimer’s-related changes are already underway. The findings also suggest that abnormal brain activity may be more than just a consequence of the disease. Reducing activity in the overactive brain circuit improved cognitive flexibility and reduced amyloid-beta accumulation, suggesting that targeting these neural networks could help slow disease progression.

Wang is hopeful that if future research confirms these findings, cognitive flexibility tests could potentially complement existing diagnostic evaluations. That may help identify people at earlier stages of the disease, perhaps years before more obvious memory symptoms appear.

“One thing that most people in the field agree on is that early diagnosis is extremely important,” Wang said. “Alzheimer’s disease is progressive. Neurons continue to degenerate over time. If we can identify the disease earlier, then treatment has a much better chance of helping.”

Source: Texas A&M University

Fish Oil Supplements May Not Prevent Alzheimer’s-related Decline

New clinical trial results show supplements with omega-3s have no effect on memory or cognitive function in older adults at risk for Alzheimer’s disease

Photo by Aleksander Saks on Unsplash

Fish oil supplements are purported to have cognitive benefits from the omega-3 fatty acids they contain, essential nutrients that help form neuron connections. But a new Keck Medicine of USC study published in eBioMedicine suggests that increasing omega-3 levels via supplements has little effect on brain health despite showing evidence that the nutrients directly reach the brain. 

The two-year, placebo-controlled, double-blinded study of older adults with an elevated risk of developing Alzheimer’s showed that high doses of omega-3s did not improve memory, cognitive function or brain cell loss in areas of the brain related to Alzheimer’s. 

“We all wish there was a silver bullet for preventing Alzheimer’s, but our findings showed that fish oil supplements do not appear to protect brain health,” said Hussein Naji Yassine, MD, director of the USC Center for Personalized Brain Health and lead investigator of the study. “While omega-3s play an important role in forming brain cell connections needed for cognition, our results do not support fish oil supplements as a preventive measure against Alzheimer’s.” 

How the study was conducted 

Researchers recruited 365 adults, ages 55 to 80 who rarely ate fish, which is rich in omega-3s, and who study authors considered at risk for Alzheimer’s. About half (47%) carried an APOE4 gene, the strongest genetic risk factor for late-onset Alzheimer’s. Participants were randomly chosen to receive either daily fish oil supplements or a placebo. The supplements contained 2000mg of docosahexaenoic acid (DHA), a key omega-3 involved in brain function. 

Researchers were first interested to learn whether the omega-3 in the supplement was able to reach the brain.  

They measured DHA levels in cerebrospinal fluid, which surrounds the brain, and found an average 17% increase of DHA levels in patients’ brains after six months, confirming the omega-3 reached its intended target. 

Next, researchers tested participants’ memory and cognitive abilities at the beginning of the study and again two years later. Study participants who took DHA supplements did no better on the tests than those who took a placebo. Brain scans also showed that supplements did not prevent shrinkage of the hippocampus, a brain region important for memory that is often used as a marker of brain aging and Alzheimer’s risk. 

Looking beyond supplements 

Now, Yassine and his team are focused on solving why omega-3 supplements can reach the brain but not affect brain health. Based on their previous research, they believe omega-3s may work better as a part of a Mediterranean-style diet, which is naturally rich in omega-3s and linked with lower Alzheimer’s risk, than in a standalone supplement. 

“We’re focused on better understanding how the brain processes omega-3s and whether factors, such as poor health, dietary pattern, genetic risk and age, may change the brain’s ability to effectively absorb and use omega-3s,” said Yassine. “We are working to develop medications that may help the brain better utilise these nutrients to preserve cognitive function.”  

Holistic lifestyle remains the best prevention  

While out of scope of the study, the researchers stress that overall healthy living – rather than relying on fish oil supplements alone – is the best way to protect brain health.

“Staying healthy throughout life remains the most powerful tool we have for reducing Alzheimer’s risk, including regular exercise, quality sleep and a balanced diet,” said Yassine. “Living a healthy lifestyle is the brain’s equivalent of getting regular car maintenance and high-quality oil changes. The brain is more likely to lose greater function if health issues in other parts of the body go unaddressed, in the same way that car engines stop working if regular maintenance is skipped.”

Source: Keck Medicine of USC

Alzheimer’s Drug Analysis May Lead to Massive Overestimate of Effectiveness

Brown University researchers say an analytic method can exaggerate the causal link between amyloid reduction and cognitive benefits of new Alzheimer’s drugs.

Neurons in the brain of an Alzheimer’s patient, with plaques caused by tau proteins. Credit: NIH

By Juan Siliezar

A statistical approach being used to support a new class of Alzheimer’s drugs may lead to overstated claims about how the drugs work, according to a new study led by researchers at the Brown University School of Public Health.

Published in JAMA Neurology, the research letter focused on quantile aggregation, a new statistical technique that divides people into groups, averages their results together and then looks for patterns across those groupings.

The letter examined how the approach works when applied to cognition and amyloid, a protein that builds up in the brains of people with Alzheimer’s disease. The approach was originally published in an analysis of Eli Lilly and Company’s Alzheimer’s drug donanemab.

“Many researchers believe reducing amyloid buildup could slow memory loss and cognitive decline associated with the disease, making it a major target for newer Alzheimer’s drugs,” said the study’s senior author Sarah Ackley, who is an assistant professor of epidemiology in the Brown University School of Public Health and runs the Computational Epidemiology Lab. “The problem is that using this method to assess the effect of amyloid removal on cognition can produce misleading results.”

The researcher’s concern is that the approach can make the link between amyloid reduction and cognitive improvement appear much stronger than it is, according to the analysis. The study the researchers looked at was a reanalysis of the original data from the randomised control trial on donanemab. It was  led by scientists affiliated with the drug maker.

“When we did simulations, we found that you could basically take a very weak relationship between amyloid and cognition and make it appear as something that looked really strong and important,” Ackley said.

The team expected there might be problems with the method but were struck by how large the effects were.

In simulations that were designed to reflect the conditions from recent trials, the team found the method showed the relationship between amyloid and cognition to be 29 times higher than its actual magnitude.

The researchers said this happens because by combining large groups of patients and averaging their results together, the process hides variability in cognitive change between patients. That can make it look like reducing amyloid is more predictive of cognitive benefit than it is.

The method also combines patients who received the drug with those who received a placebo. Without that randomization, the analysis cannot reliably determine whether amyloid reduction is actually causing cognitive benefit or whether other factors are at play, according to the study.

To illustrate this, the team also tested quantile aggregation using data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease Study that ran from 2014 to 2023.  That trial tested if the drug solanezumab could slow cognitive decline in older adults with elevated amyloid levels in their brains, an early sign associated with Alzheimer’s disease.

The trial showed solanezumab did not slow cognitive decline, yet when the team ran the data from that trial through the analysis of donanemab using the quantile aggregation method, it came back showing a strong link between lower amyloid and better cognitive outcomes.

“We basically built a case that this method is going to give you misleading results,” Ackley said. “It made a failed trial look like it had successfully removed amyloid and that the removal of amyloid had reduced cognitive decline. In reality, the drug did neither of these things.”

Ackley emphasized that the findings do not settle the broader question of how the new Alzheimer’s disease drugs work. Instead, she says, the work highlights a need for more rigorous statistical methods.   She also emphasized the need for more data sharing in Alzheimer’s research, especially as new  treatments become more widely used and covered by public programs like Medicare.

“Our study was simple, but a great demonstration of the value of academic research,” she said. “Working outside of industry incentives gave us the freedom to closely examine a methodological issue affecting how some of the most consequential new drugs are understood.” 

Source: Brown University